Trial · NCT01776424
Participant flow27
How many started, completed or left each group, period by period.
1 to 20 of 27
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Antithrombotic Part (Double Blind) | STARTED | Rivaroxaban 2.5mg + Aspirin 100mg | 9,152 | |
| Antithrombotic Part (Double Blind) | STARTED | Rivaroxaban 5mg + Aspirin Placebo | 9,117 | |
| Antithrombotic Part (Double Blind) | STARTED | Rivaroxaban Placebo + Aspirin 100mg | 9,126 | |
| Antithrombotic Part (Double Blind) | Treated With Antithrombotic Treatment | Rivaroxaban 2.5mg + Aspirin 100mg | 9,134 | |
| Antithrombotic Part (Double Blind) | Treated With Antithrombotic Treatment | Rivaroxaban 5mg + Aspirin Placebo | 9,109 | |
| Antithrombotic Part (Double Blind) | Treated With Antithrombotic Treatment | Rivaroxaban Placebo + Aspirin 100mg | 9,107 | |
| Antithrombotic Part (Double Blind) | Randomized to Study Pantoprazole/Placebo | Rivaroxaban 2.5mg + Aspirin 100mg | 5,878 | |
| Antithrombotic Part (Double Blind) | Randomized to Study Pantoprazole/Placebo | Rivaroxaban 5mg + Aspirin Placebo | 5,859 | |
| Antithrombotic Part (Double Blind) | Randomized to Study Pantoprazole/Placebo | Rivaroxaban Placebo + Aspirin 100mg | 5,861 | |
| Antithrombotic Part (Double Blind) | COMPLETED | Rivaroxaban 2.5mg + Aspirin 100mg | 9,132 | |
| Antithrombotic Part (Double Blind) | COMPLETED | Rivaroxaban 5mg + Aspirin Placebo | 9,098 | |
| Antithrombotic Part (Double Blind) | COMPLETED | Rivaroxaban Placebo + Aspirin 100mg | 9,102 | |
| Antithrombotic Part (Double Blind) | NOT COMPLETED | Rivaroxaban 2.5mg + Aspirin 100mg | 20 | |
| Antithrombotic Part (Double Blind) | NOT COMPLETED | Rivaroxaban 5mg + Aspirin Placebo | 19 | |
| Antithrombotic Part (Double Blind) | NOT COMPLETED | Rivaroxaban Placebo + Aspirin 100mg | 24 | |
| LTOLE Part (Open Label) | STARTED | Rivaroxaban 2.5mg + Aspirin 100mg | 4,399 | |
| LTOLE Part (Open Label) | STARTED | Rivaroxaban 5mg + Aspirin Placebo | 4,292 | |
| LTOLE Part (Open Label) | STARTED | Rivaroxaban Placebo + Aspirin 100mg | 4,273 | |
| LTOLE Part (Open Label) | Treated in LTOLE Part | Rivaroxaban 2.5mg + Aspirin 100mg | 4,379 | |
| LTOLE Part (Open Label) | Treated in LTOLE Part | Rivaroxaban 5mg + Aspirin Placebo | 4,274 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01776424/flow